Navigation Links
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
Date:4/24/2009

day, April 25, 2009.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- According to statistics released by the American Society of ... fillers, such as the JUVEDERM ® family of fillers ... between 2013 to 2014, HA filler treatments increased by 8 ... which shows U.S. unit sales of HA dermal fillers were ... "These findings are consistent with what I see every day ...
(Date:3/2/2015)... , March 2, 2015 Cardinal Health today ... a leading global manufacturer of cardiology and endovascular devices, ... net of the present value of tax benefits. The ... of $1.0 billion in new senior unsecured notes and ... to close in the United States ...
(Date:3/2/2015)... and BETHESDA, Md. , March ... company focused on treating and preventing autoimmune diseases, announced ... monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... agreement, Celimmune has the rights to develop, manufacture and ... Japan . Concurrently, Amgen has been granted ...
Breaking Medicine Technology:Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 2Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 3Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 4Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 5Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 6Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 7Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 2Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 4Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 5Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 6Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 7Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3
(Date:3/2/2015)... March 02, 2015 ProvidaStaff ... for its educational healthcare division to EDU Healthcare ... healthcare services to school systems and students nationwide. , ... to school districts throughout the country,” said Angela M. ... be a better organization and the introduction of EDU ...
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... 2015 To help healthcare ... their practices compliantly and profitably, MDreferralPRO and ... The interoperability between a strategic referral ... practice management system is necessary for a ... A referral management and development solution relies ...
(Date:3/1/2015)... As residents and business owners ... Burns and Carita Weaver, believe in supporting local ... the Southlake Chamber of Commerce, Carroll Independent School ... launched a website for Southlake mayoral candidate Laura ... tool for Hill’s campaign, the website combines images, ...
(Date:3/1/2015)... Birmingham, Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... BOTOX® , which is approved to treat Overactive Bladder (OAB) ... urgency and frequency in adults when another type of medication ... This is a different treatment option that takes another ... itself. , BOTOX® works on the nerves and ...
Breaking Medicine News(10 mins):Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... ... Company, a leading supplier of industrial and technical parts and free CAD images ... input from their customers. John Carrier, the company,s President, says the new ReidSupply.com ... and a de-emphasis on marketing. The new site takes the customer exactly where ...
... during a Caesarean section helps manage pain after the ... Cochrane Researchers. The researchers recommend local anaesthetics as part ... provided that consideration is given to the cost. ... the growing number of women giving birth by Caesarean ...
... , LOS ANGELES, July 7 /PRNewswire-USNewswire/ -- A ... upcoming "Be a Hero for Babies Day" to raise funds ... moms have full-term pregnancies and healthy babies. , , Make a ... and the gift will double in value thanks to ...
... for U.S. research dollars, NIH says , MONDAY, July ... guidelines Monday describing which embryonic stem cell lines will ... of stem cells that can be used for research. ... that embryonic stem cells used in research were obtained ...
... Laboratories, a national clinical and anatomic pathology reference laboratory ... announced today the appointment of Sherrie L. Perkins, MD, ... laboratories, effective, July 1, 2009. , , Dr. ... R. Ashwood, MD, who will be transitioning into the ...
... Eli Lilly and Company (NYSE: LLY ) will ... Wednesday, July 22, 2009. Lilly will also conduct a conference ... further detail the company,s financial performance. , , The ... EDT. Investors, media and the general public can access a ...
Cached Medicine News:Health News:Customers Design Reid Supply's New Web Site 2Health News:Customers Design Reid Supply's New Web Site 3Health News:Customers Design Reid Supply's New Web Site 4Health News:Customers Design Reid Supply's New Web Site 5Health News:Farmers Insurance Pledges to Match All Donations Up to $250k For "Be a Hero for Babies Day" to Benefit March Of Dimes 2Health News:Final Rules Broaden Pool for Stem Cell Research 2Health News:Final Rules Broaden Pool for Stem Cell Research 3Health News:Final Rules Broaden Pool for Stem Cell Research 4Health News:ARUP Laboratories Announces New CMO Appointment 2
... OTI's new Spectral system is a combination ... Laser Ophthalmoscope (SLO) system that provides suberb, ... choroidal-retina structure. With the advancements of spectral ... of up to 27,000 A-Scans per second ...
... Arctic Circler uses the same cryoconsole ... AF originating in the pulmonary veins. Arctic ... challenge the traditional palliative-only treatments that rely ... the Arctic Circler catheter has the ability ...
The KMedic Jet Wire Twister is designed to provide fast, smooth and even twisting of soft wire, saving time in the O.R. Now available for the first time in stainless steel. Suitable for the entire ra...
Osteophyte periosteal elevator for bone removing....
Medicine Products: